Champlain Investment Partners LLC Raises Holdings in Repligen Co. (NASDAQ:RGEN)

Champlain Investment Partners LLC increased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,543,530 shares of the biotechnology company's stock after acquiring an additional 122,595 shares during the period. Repligen makes up about 1.4% of Champlain Investment Partners LLC's portfolio, making the stock its 18th biggest holding. Champlain Investment Partners LLC owned about 2.75% of Repligen worth $222,176,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new position in shares of Repligen during the 4th quarter valued at about $29,000. UMB Bank n.a. lifted its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the period. Global Retirement Partners LLC boosted its stake in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after buying an additional 129 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Repligen during the fourth quarter worth about $55,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Evercore ISI assumed coverage on Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. Canaccord Genuity Group cut their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Royal Bank of Canada upped their price target on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a report on Friday, February 21st. Finally, HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Repligen presently has an average rating of "Hold" and an average price target of $176.82.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction dated Monday, March 17th. The shares were acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by insiders.

Repligen Trading Up 6.0 %

RGEN traded up $7.92 during trading hours on Tuesday, reaching $139.56. The company's stock had a trading volume of 557,218 shares, compared to its average volume of 707,670. The stock has a market cap of $7.84 billion, a PE ratio of -273.13, a P/E/G ratio of 4.54 and a beta of 1.27. Repligen Co. has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business's 50-day moving average is $140.09 and its 200-day moving average is $145.74.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities research analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.